Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMGJL16)

Drug Name
LE-300 Drug Info
Synonyms L 8401; LE 300; 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Preclinical [1]
Cross-matching ID
PubChem CID
4350931
ChEBI ID
CHEBI:92030
CAS Number
CAS 274694-98-3
TTD Drug ID
DMGJL16

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D5 receptor (D5R) TTS2PH3 DRD5_HUMAN Antagonist [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Dopamine D5 receptor (D5R) DTT DRD5 7.097 6.724 6.896 7.369
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 06 Mental, behavioural or neurodevelopmental disorder
Disease Class ICD-11: 6A20 Schizophrenia
The Studied Tissue Pre-frontal cortex
The Studied Disease Schizophrenia [ICD-11:6A20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D5 receptor (D5R) DTT DRD5 2.59E-01 -0.06 -0.18
Dopamine D5 receptor (D5R) DTT DRD5 8.63E-01 -0.01 -0.08
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.